cGAMP (Cyclic AMP-GMP) (Synonyms: Cyclic GMP-AMP; 3',3'-cGAMP) |
Catalog No.GC31696
One-Click Copy Product Info
|
cGAMP (Cyclic AMP-GMP) is a cyclic dinucleotide that acts as a second messenger in mammalian cells and is synthesized "on demand" when cells are threatened.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 849214-04-6
Sample solution is provided at 25 µL, 10mM.
cGAMP (Cyclic AMP-GMP) is a cyclic dinucleotide that acts as a second messenger in mammalian cells and is synthesized "on demand" when cells are threatened[1, 2]. cGAMP activates the stimulator of interferon genes (STING), triggering a signaling cascade that leads to the production of type I interferons and other immune mediators[3]. Under cGAMP stimulation, cells show increased IFNB1 transcription, but no abnormal transcription of genes encoding interleukin-1 (IL1), interleukin-6 (IL6), or tumor necrosis factor (TNF)[4].
In vitro, treatment of mouse bone marrow-derived dendritic cells and human peripheral blood mononuclear cell-derived dendritic cells with cGAMP (5mg/mL, 60mg/mL) for 24h directly activated both mouse and human dendritic cells. The purity of CD11c+ cells in the tested cell populations was 95% for human peripheral blood mononuclear cell-derived dendritic cells and 82% for mouse bone marrow-derived dendritic cells[5].
In vivo, cGAMP (5μg) administered as a nasal mucosal adjuvant to immunized mice promoted antigen-specific proliferation of mouse splenocytes and enhanced antigen-specific humoral immune responses[5].
References:
[1] Liu Y, Fei Y, Wang X, et al. Biomaterial-enabled therapeutic modulation of cGAS-STING signaling for enhancing antitumor immunity[J]. Molecular Therapy, 2023, 31(7): 1938-1959.
[2] Su Y. Development of Riboswitch-based Sensors for High-throughput Enzyme Activity Screens[M]. University of California, Berkeley, 2018.
[3] Kaushal A. A central role of stimulator of interferon genes’ adaptor protein in defensive immune response[J]. Immunologic Research, 2025, 73(1): 39.
[4] Liu Y, Jesus A A, Marrero B, et al. Activated STING in a vascular and pulmonary syndrome[J]. New England Journal of Medicine, 2014, 371(6): 507-518.
[5] Škrnjug I, Guzmán C A, Ruecker C. Cyclic GMP-AMP displays mucosal adjuvant activity in mice[J]. PloS one, 2014, 9(10): e110150.
| Cell experiment [1]: | |
Cell lines | Murine bone marrow-derived dendritic cells, human PBMC-derived dendritic cells |
Preparation Method | Murine bone marrow-derived dendritic cells (DCs) and human PBMC-derived DCs were stimulated in vitro with c-di-AMP, cGAMP (both at 5mg/mL or 60mg/mL) or left untreated (mock) for 24h. The dendritic cells were decorated with fluorophore-conjugated antibodies against the DC activation markers CD40, CD54, CD80, CD83, CD86 or MHC class II (I-Ab) and analyzed by flow cytometry. |
Reaction Conditions | 5mg/mL, 60mg/mL; 24h |
Applications | cGAMP directly activates murine and human dendritic cells in vitro. The purity of the tested cell populations with respect to CD11c+ cells was 95% for the human PBMC derived DCs and 82% for the mouse bone marrow-derived DCs. |
| Animal experiment [1]: | |
Animal models | Female C57BL/6 (H-2b) mice |
Preparation Method | Mouse immunization experiments Five animals per group were immunized intra-nasal (i. n.) on days 0, 14 and 28. Animals were anesthetized with Isoflurane and treated 10mL per nostril with 15μg ovalbumin (OVA) alone or co-adminis tered with 5μg per dose of c-di-AMP, cGAMP or cholera toxin B subunit (CTB) in Ampuwa or with Ampuwa alone in the control group (mock immunization). On day 42 after immunization animals were sacrificed and samples were collected. |
Dosage form | 5μg; intra-nasal (i. n.) |
Applications | The cGAMP-dependent enhanced specific IgG and IgA titers in our mouse immunization experiments suggest that the use of cGAMP promotes the antigen-specific humoral immune response. Spleen cells from mice immunized with cGAMP-adjuvanted antigen showed a facilitated antigen-specific proliferation capacity. |
References: | |
| Cas No. | 849214-04-6 | SDF | |
| Synonyms | Cyclic GMP-AMP; 3',3'-cGAMP | ||
| Canonical SMILES | O=P(O[C@H]1[C@@H](O)[C@H](N2C=NC3=C2N=CN=C3N)O[C@@H]1COP4(O)=O)(O)OC[C@@H]5[C@@H](O4)[C@@H](O)[C@H](N6C=NC7=C6N=C(N)NC7=O)O5 | ||
| Formula | C20H24N10O13P2 | M.Wt | 674.41 |
| Solubility | Water : 20 mg/mL (29.66 mM) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.4828 mL | 7.4139 mL | 14.8278 mL |
| 5 mM | 296.6 μL | 1.4828 mL | 2.9656 mL |
| 10 mM | 148.3 μL | 741.4 μL | 1.4828 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
Average Rating: 5 (Based on Reviews and 38 reference(s) in Google Scholar.)